15:06 , Sep 1, 2017 |  BC Week In Review  |  Company News

Janssen gains MDD compound CERC-501 from Cerecor

Cerecor Inc. (NASDAQ:CERC) divested its CERC-501 to the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) for $25 million and up to $20 million in regulatory milestones. Janssen will assume responsibility for ongoing clinical...
21:20 , Feb 10, 2017 |  BC Week In Review  |  Clinical News

CERC-301: Ph II Clin301-203 data

Last November, Cerecor reported top-line data from the double-blind, U.S. Phase II Clin301-203 trial in 115 MDD patients showing that adjunctive treatment with 12 and 20 mg oral CERC-301 on days 0 and 7 each...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

CERC-301: Completed Phase II enrollment

Cerecor completed enrollment of 115 patients in the double-blind, placebo-controlled, U.S. Phase II Clin301-203 trial evaluating 12 and 20 mg oral CERC-301 once weekly for 2 weeks. The trial enrolled patients who experienced a severe...
02:24 , Oct 16, 2015 |  BC Extra  |  Financial News

Cerecor raises $26M in IPO

Cerecor Inc. (NASDAQ:CERCU) lost $0.10 to $6.40 in its first day of trading Thursday after it raised $26 million through the sale of 4 million units at $6.50 in an IPO underwritten by Maxim Group...
07:00 , Sep 7, 2015 |  BC Week In Review  |  Clinical News

CERC-301: Phase II started

Cerecor began the double-blind, placebo-controlled, U.S. Phase II Clin301-202 trial to evaluate 12 and 20 mg oral CERC-301 once weekly for 2 weeks in about 104 patients. Clin301-202 is enrolling patients who are experiencing a...
07:00 , Mar 30, 2015 |  BC Week In Review  |  Clinical News

CERC-301: Phase II data

A double-blind, U.S. Phase II trial in 135 patients with MDD who recently experienced active suicidal ideation despite treatment with selective serotonin reuptake inhibitors (SSRI) or serotonin/norepinephrine reuptake inhibitors (SNRI) showed that adjunctive treatment with...
01:23 , Jul 22, 2014 |  BC Extra  |  Top Story

Cerecor raises $15 million in B round

Cerecor Inc. (Baltimore, Md.) raised $15 million in the first tranche of a planned $32 million series B round. New investors New Enterprise Associates; Apple Tree Partners; and MPM Capital led the tranche. Cerecor's CERC-301...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Clinical News

CERC-301 regulatory update

FDA granted Fast Track designation to CERC-301 to treat major depressive disorder (MDD). Cerecor expects data from a Phase II trial with the small molecule NMDA receptor NR2B subtype ( GRIN2B ; NR2B) antagonist to...
08:00 , Nov 18, 2013 |  BC Week In Review  |  Clinical News

MK-0657: Phase II started

Cerecor began a double-blind Phase II trial to evaluate 8 or 12 mg CERC-301 in about 135 patients with MDD who had a recent active suicidal ideation and are failing treatment with selective serotonin reuptake...
07:00 , Oct 24, 2013 |  BC Innovations  |  Strategy

Synaptic synopsis

The early promise that neurotransmitter research would unlock the door for neurological diseases has devolved into sagging interest from several pharmas following repeated failures in clinical trials. Now, genetic findings are pointing to new targets...